| Authors: |
Penter L; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA, USA.; Harvard Medical School, Boston, MA, USA.; Department of Hematology, Oncology, and Tumorimmunology, Campus Virchow Klinikum, Berlin, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; Berlin Institute of Health at Charité - Universitätsmedizin Berlin, BIH Biomedical Innovation Academy, BIH Charité Digital Clinician Scientist Program, Charitéplatz 1, 10117, Berlin, Germany., Borji M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA, USA.; Translational Immunogenomics Lab, Dana-Farber Cancer Institute, Boston, MA, USA., Nagler A; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA, USA., Lyu H; Translational Immunogenomics Lab, Dana-Farber Cancer Institute, Boston, MA, USA., Lu WS; Translational Immunogenomics Lab, Dana-Farber Cancer Institute, Boston, MA, USA., Cieri N; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA, USA.; Harvard Medical School, Boston, MA, USA., Maurer K; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA, USA.; Harvard Medical School, Boston, MA, USA., Oliveira G; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA, USA.; Harvard Medical School, Boston, MA, USA., Al'Khafaji AM; Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA, USA., Garimella KV; Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA, USA., Li S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA, USA.; Translational Immunogenomics Lab, Dana-Farber Cancer Institute, Boston, MA, USA., Neuberg DS; Department of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA., Ritz J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA., Soiffer RJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA., Garcia JS; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Livak KJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Translational Immunogenomics Lab, Dana-Farber Cancer Institute, Boston, MA, USA., Wu CJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. catherine_wu@dfci.harvard.edu.; Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA, USA. catherine_wu@dfci.harvard.edu.; Harvard Medical School, Boston, MA, USA. catherine_wu@dfci.harvard.edu.; Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA. catherine_wu@dfci.harvard.edu. |
